Menu
Recruiting NCT05940272

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

No phase Interventional Lymphoma, B-Cell Lymphoma Large-cell Lymphoma Large B-cell Lymphoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Hematolo-GIST Training, Participants Appointment.
Who it may be relevant to
Registry conditions: Lymphoma, B-Cell, Lymphoma, Large-cell Lymphoma, Large B-cell Lymphoma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers

Overview

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Interventions

  • Behavioral Hematolo-GIST Training
    Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
  • Behavioral Participants Appointment
    Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.

Primary outcome measures

  • Feasibility of the Hematolo-GIST intervention among hematologists and participants [Time frame: Up to 1 year]

Eligibility criteria

Inclusion criteria

Providers

  • Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)

Patients

  • Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
  • Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
  • Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
  • Self-identify as Black and/or White
  • Per medical record, 18 years of age or older
  • Per self-report, fluent in English\*\*
  • Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
  • How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
  • What is your preferred language for healthcare? (must respond English)

Exclusion criteria

Providers

  • Per self-report, planning to leave the cancer center in the next 12 months

Patients

  • Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
  • Per research staff judgment and/or self-report, too ill or weak to complete study procedures
  • Per medical record or self-report, receiving hospice care at the time of enrollment

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

United States · 2 centers
  • Memorial Sloan Kettering Cancer Center (All protocol activities) — New York
  • NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only) — New York

Identifiers

NCT: NCT05940272 · 23-164

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗